Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ 7,028,000	$ (33,226,000)	$ (95,304,000)
Adjustments to reconcile net income (loss) to net cash (used in) provided by operating activities:
Depreciation and amortization	1,690,000	2,486,000	7,430,000
Impairment of intangible asset	0	0	66,087,000
Remeasurement of acquisition-related contingent consideration	3,327,000	845,000	(22,731,000)
Remeasurement of financing-related contingent consideration	435,000	378,000	(1,899,000)
Amortization of debt discount and debt issuance costs	6,524,000	5,995,000	4,830,000
Changes in deferred tax	(7,431,000)	(6,334,000)	(19,152,000)
Share-based compensation expense	2,999,000	519,000	7,852,000
Gain on sale of Hospital Products	(45,760,000)	0	0
Loss on deconsolidation of subsidiary	0	1,750,000	0
Gain from release of certain liabilities	(3,364,000)	0	0
Other adjustments	142,000	(254,000)	4,188,000
Net changes in assets and liabilities
Accounts receivable	8,281,000	2,471,000	3,452,000
Inventories, net	(1,352,000)	1,155,000	711,000
Prepaid expenses and other current assets	1,863,000	(1,187,000)	3,577,000
Research and development tax credit receivable	2,213,000	(1,014,000)	(2,545,000)
Accounts payable & other current liabilities	(2,788,000)	4,641,000	(2,032,000)
Deferred revenue	0	(114,000)	(1,892,000)
Accrued expenses	(13,226,000)	357,000	(10,640,000)
Earn-out payments for contingent consideration in excess of acquisition-date fair value	(5,323,000)	(10,988,000)	(19,468,000)
Royalty payments for contingent consideration payable in excess of original fair value	(866,000)	(1,748,000)	(2,838,000)
Other assets and liabilities	(3,126,000)	(4,057,000)	(2,342,000)
Net cash used in operating activities	(48,734,000)	(38,325,000)	(82,716,000)
Cash flows from investing activities:
Purchases of property and equipment	(98,000)	(29,000)	(178,000)
Proceeds from disposal of property and equipment	0	154,000	0
Proceeds from the disposition of the Hospital Products	25,500,000	0	0
Purchase of intangible assets	0	0	(20,000,000)
Proceeds from sales of marketable securities	36,284,000	63,246,000	359,507,000
Purchases of marketable securities	(131,407,000)	(24,648,000)	(376,310,000)
Net cash (used in) provided by investing activities	(69,721,000)	38,723,000	(36,981,000)
Cash flows from financing activities:
Proceeds from debt issuance	0	0	143,750,000
Payments for debt issuance costs	0	0	(6,190,000)
Exercise of warrants	0	0	2,911,000
Proceeds from the February 2020 private placement	60,570,000	0	0
Proceeds from the May 2020 public offering	116,924,000	0	0
Proceeds from issuance of ordinary shares	2,189,000	118,000	577,000
Share repurchases	0	0	(27,637,000)
Other financing activities, net	0	(145,000)	(752,000)
Net cash provided by (used in) financing activities	179,683,000	(27,000)	112,659,000
Effect of foreign currency exchange rate changes on cash and cash equivalents	720,000	78,000	(201,000)
Net change in cash and cash equivalents	61,948,000	449,000	(7,239,000)
Cash and cash equivalents at January 1	9,774,000	9,325,000	16,564,000
Cash and cash equivalents at December 31	71,722,000	9,774,000	9,325,000
Supplemental disclosures of cash flow information:
Income taxes (refund) paid, net	(1,701,000)	140,000	776,000
Interest paid	$ 6,469,000	$ 6,469,000	$ 3,359,000